Latest:
Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma
Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.
Authors
Anne Chiang, MD, PhD, Yale Cancer Center
Latest:
Patient Conversations and Considerations in the Extensive-Stage Relapse Setting
Panelists emphasized that clear, compassionate, and ongoing communication with patients diagnosed with small cell lung cancer is vital to support informed decision-making amid evolving treatment options, highlighting the importance of maintaining a broad therapeutic arsenal, integrating multidisciplinary and palliative care early, and regularly reassessing goals to optimize quality of life and treatment outcomes throughout the often prolonged disease course.
Bradley J. Monk, MD, FACS, FACOG
Latest:
Treatment Strategies in Non-Responders to Chemotherapy
Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.
Ashkan Emadi, MD, PhD
Latest:
Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD
Ashkan Emadi, MD, PhD, discusses how the combination of venetoclax plus pegcrisantaspase induced complete remissions in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.